PDS Biotechnology

#药闻简讯# 2026 年 1 月 9 日——专注于改变免疫系统靶向和杀伤癌细胞方式的后期免疫疗法公司$PDS Biotechnology(PDSB)$ 今日宣布，公司已向美国食品药品监督管理局（FDA）提交了其 3 期 VERSATILE-003 临床试验的方案修订申请。此次修订将 VERSATILE-003 3 期临床试验的无进展生存期（PFS）终点...

$PDS Biotechnology(PDSB)$ S-8 Securities to be offered to employees in employee benefit plans Accession Number: 0001140361-25-045394  Act: 33  Size: 969 KB 网页链接

$PDS Biotechnology(PDSB)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001140361-26-001958  Act: 34  Size: 178 KB 网页链接

$PDS Biotechnology(PDSB)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001140361-25-041976  Act: 34  Size: 9 MB 网页链接

$PDS Biotechnology(PDSB)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001140361-25-044940  Act: 34  Size: 180 KB 网页链接

$PDS Biotechnology(PDSB)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001140361-25-041805  Act: 34  Size: 286 KB 网页链接

$PDS Biotechnology(PDSB)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001140361-26-002608  Act: 34  Size: 181 KB 网页链接

$PDS Biotechnology(PDSB)$ 424B5 Prospectus [Rule 424(b)(5)] Accession Number: 0001140361-25-041557  Act: 33  Size: 501 KB 网页链接

$PDS Biotechnology(PDSB)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001140361-25-041286  Act: 34  Size: 197 KB 网页链接

$PDS Biotechnology(PDSB)$ 8-K Current report, items 1.01, 2.02, 7.01, 8.01, and 9.01 Accession Number: 0001140361-25-041563  Act: 34  Size: 830 KB 网页链接

$PDS Biotechnology(PDSB)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001140361-25-043889  Act: 34  Size: 179 KB 网页链接

$PDS Biotechnology(PDSB)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001140361-26-000786  Act: 34  Size: 178 KB 网页链接